Renal cell cancer: Overview and immunochemotherapy

Carcinoma of the Kidney

Volumn , Issue , 2007, Pages 1-16

  Khoo, Vincent ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861636963     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545436.003     Document Type: Chapter

References (48)

1. http://www.cancerhelp.org.uk. Kidney Cancer. 2007.
2. http://www.cancer.org/docroot/CRI/CRI_2x.asp?sitearea=&dt=22
3. W. H. Chow, S. S. Devesa, J. L. Warren et al., Rising incidence of renal cell cancer in the United States. JAMA, 281:17 (1999), 1628-31.
4. A. Mathew, S.S. Devesa, J.F. Fraumeni Jr. et al., Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev, 11:2 (2002), 171-8.
5. W. H. Chow, G. Gridley, J. F. Fraumeni Jr. et al., Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med, 343:18 (2000), 1305-11.
6. A. H. Smith, V. I. Shearn, and R. Wood, Asbestos and kidney cancer: the evidence supports a causal association. Am J Ind Med, 16:2 (1989), 159-66.
7. P. N. Bretan, Jr. M. P. Busch, H. Hricak et al.,. Chronic renal failure: a significant risk factor in the development of acquired renal cysts and renal cell carcinoma. Case reports and review of the literature. Cancer, 57:9 (1986), 1871-9.
8. D. G. Skinner, T. R. Pritchett, G. Lieskovsky et al., Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg, 210:3 (1989), 387-92, discussion 392-4.
9. B. Delahunt, and J. N. Eble, History of the development of the classification of renal cell neoplasia. Clin Lab Med, 25:2 (2005), 231-46.
10. N. Barnabas, M. B. Amin, K. Pindolia et al., Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma. J Surg Oncol, 80:1 (2002), 52-60.
11. R. E. Banks, P. Tirukonda, C. Taylor et al., Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res, 66:4 (2006), 2000-11.
12. M. B. Amin, P. Tamboli, J. Javidan et al., Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol, 26:3 (2002), 281-91.
13. J. J. Patard, E. Leray, N Rioux.A. Leclercq et al., Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol, 23:12 (2005), 2763-71.
14. A. Zisman, A. J. Pantuck, F. Dorey et al., Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol, 19:6 (2001), 1649-57.
15. A. Zisman, A. J. Pantuck, R. A. Figlin et al., Validation of the Ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol, 19:17 (2001), 3792-3.
16. J. J. Patard, H. L. Kim, J. S. Lam et al., Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. JClin Oncol, 22:16 (2004), 3316-22.
17. R. J. Motzer, M. Mazumdar, J. Bacik et al., Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17:8 (1999), 2530-40.
18. R. J. Motzer, J. Bacik, L. H. Schwartz et al., Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol, 22:3 (2004), 454-63.
19. R. J. Motzer, M. Mazumdar, J. Bacik et al., Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol, 18:9 (2000), 1928-35.
20. L. Cindolo, J. J. Patard, P. Chiodini et al., Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer, 104:7 (2005), 1362-71.
21. M. H. Bui, D. Seligson, K. R. Han et al., Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res, 9:2 (2003), 802-11.
22. M. H. Bui, H. Visapaa, D. Seligson et al., Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol, 171:6 (Pt 1) (2004), 2461-6.
23. R. J. Motzer, N. H. Bander, and D. M. Nanus, Renal-cell carcinoma. N Engl J Med, 335:12 (1996), 865-75.
24. J. S. Lam, O. Shvarts, J T Leppert, R. A. Figlin, and A. S. Belldegrun, Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol, 173:6 (2005), 1853-62.
25. C. Coppin, F. Porzsolt, J. Kumpf et al., Immunotherapy for advanced renal cell cancer. Cochrane Database SystRev 3 (2000), CD001425.
26. N. B. Itano, M. L. Blute, B. Spotts et al., Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol, 164:2 (2000), 322-5.
27. E. W. Riches, I. H. Griffiths, and A. C. Thackray, New growths of the kidney and ureter. Br J Urol, 23:4 (1951), 297-356.
28. R. H. Flocks and M. C. Kadesky, Malignant neoplasms of the kidney; an analysis of 353 patients for followed five years or more. J Urol, 79:2 (1958), 196-201.
29. D. G. Bratherton, The place of radiotherapy in the treatment of hypernephroma. Br J Radiol, 42:504 (1969), 949.
30. W. B. Peeling, B. S. Mantell, and B. G. Shepheard, Post-operative irradiation in the treatment of renal cell carcinoma. Br J Urol, 41:1 (1969), 23-31.
31. B. van der Werf-Messing, Proceedings: Carcinoma of the kidney. Cancer, 32:5 (1973), 1056-61.
32. H. Juusela, K. Malmio, O. Alfthan et al., Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol, 11:3 (1977), 277-81.
33. R. Finney, The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br J Urol, 45:3 (1973), 258-69.
34. M. Kjaer, P. L. Frederiksen, and S. A. Engelholm, Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys, 13:5 (1987), 665-72.
35. G. H. Mickisch, A. Garin, H. van Poppel et al., Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358:9286 (2001), 966-70.
36. R. C. Flanigan, S. E. Salmon, B. A. Blumenstein et al., Nephrectomy followed by interferon alfa- 2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 345:23 (2001), 1655-9.
37. E. C. Halperin and L. Harisiadis, The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer, 51:4 (1983), 614-17.
38. V. Onufrey and M. Mohiuddin, Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys, 11:11 (1985), 2007-9.
39. A. Yagoda, B. Abi-Rached, and D. Petrylak, Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol, 22:1 (1995), 42-60.
40. C. Coppin, F. Porzsolt, A. Awa et al., Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, 1 (2005), CD001425.
41. C. Coppin, F. Porzsolt, M. Autenrieth et al., Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2007) 1 (2007).
42. J. M. Larkin and M. E. Gore, The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs. interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin Oncol (R Coll Radiol), 17:5 (2005), 319-21.
43. D. J. Hicklin and L.M Ellis. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23:5 (2005), 1011-27.
44. J. C. Yang, R. M. Sherry, S. M. Steinberg et al., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol, 21:16 (2003), 3127-32.
45. S. Wilhelm, C. Carter, M. Lynch et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5:10 (2006), 835-44.
46. B. Escudier, T. Eisen, W. M. Stadler et al., Sorafenib in advanced clear-cell renal-cell carcinoma. NEngl J Med, 356:2 (2007), 125-34.
47. R. J. Motzer, M.D. Michaelson, B. G. Redman et al., Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24:1 (2006), 16-24.
48. R. J. Motzer, T. E. Hutson, P. Tomczak et al., Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med, 356:2 (2007), 115-24.